ADGRL4 and neoplasm: Although bevacizumab was capable of decreasing this drastic change in perfusion rate, it seems that bevacizumab therapy may not be as effective in normalizing microvascularity within the tumour regions compared to anti‐ELTD1 and OKN therapies.